emodin has been researched along with Fatty Liver, Nonalcoholic in 9 studies
Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.
emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the influence of emodin on methionine-choline-deficient (MCD) diet-induced non-alcoholic fatty liver disease (NAFLD) in mice." | 7.81 | [Emodin worsens methionine-choline-deficient diet-induced non-alcoholic fatty liver disease in mice]. ( Liu, Q; Shi, M; Wang, F; Yu, F; Yu, N, 2015) |
| "Emodin (EMO) is a major bioactive constituent of CMD that has apparent therapeutic efficacy against obesity and fatty liver." | 5.62 | Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway. ( Cai, J; Deng, Z; Guo, J; Huang, Q; Lan, S; Liu, H; Liu, M; Liu, Z; Pan, Z; Shen, C; Si, Y; Tu, H; Wu, H; Wu, S; Xian, S; Xin, X; Yu, Y; Zhang, J; Zheng, M; Zhong, C; Zhong, Y; Zhu, Z, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) has become a predictor of death in many diseases." | 5.56 | Radix Polygoni Multiflori and Its Main Component Emodin Attenuate Non-Alcoholic Fatty Liver Disease in Zebrafish by Regulation of AMPK Signaling Pathway. ( Dai, X; Gong, L; Hu, N; Li, Y; Tang, Y; Wang, C; Yu, L; Zheng, L, 2020) |
| "To investigate the influence of emodin on methionine-choline-deficient (MCD) diet-induced non-alcoholic fatty liver disease (NAFLD) in mice." | 3.81 | [Emodin worsens methionine-choline-deficient diet-induced non-alcoholic fatty liver disease in mice]. ( Liu, Q; Shi, M; Wang, F; Yu, F; Yu, N, 2015) |
| "And a rat model of NAFLD was established by feeding high-fat diet." | 1.91 | Study on the mechanism of Shuganzhi Tablet against nonalcoholic fatty liver disease and lipid regulation effects of its main substances in vitro. ( Feng, S; Han, H; Shi, M; Tang, J; Wang, L; Zhang, T, 2023) |
| "In animal models of NAFLD, AE, and RH significantly improved the pathological symptoms of steatosis and fibrosis and reduced the levels of pro-inflammatory factors via the NF-κB/NLRP3 pathway." | 1.91 | Active ingredients of Erhuang Quzhi Granules for treating non-alcoholic fatty liver disease based on the NF-κB/NLRP3 pathway. ( Chen, W; Li, S; Ma, Y, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases and has become a huge public health issue worldwide." | 1.72 | Rhubarb free anthraquinones improved mice nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome. ( Azami, NLB; Bian, Y; Lu, B; Ma, F; Sun, M; Wang, D; Wei, G; Wu, C, 2022) |
| "Emodin (EMO) is a major bioactive constituent of CMD that has apparent therapeutic efficacy against obesity and fatty liver." | 1.62 | Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway. ( Cai, J; Deng, Z; Guo, J; Huang, Q; Lan, S; Liu, H; Liu, M; Liu, Z; Pan, Z; Shen, C; Si, Y; Tu, H; Wu, H; Wu, S; Xian, S; Xin, X; Yu, Y; Zhang, J; Zheng, M; Zhong, C; Zhong, Y; Zhu, Z, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) has become a predictor of death in many diseases." | 1.56 | Radix Polygoni Multiflori and Its Main Component Emodin Attenuate Non-Alcoholic Fatty Liver Disease in Zebrafish by Regulation of AMPK Signaling Pathway. ( Dai, X; Gong, L; Hu, N; Li, Y; Tang, Y; Wang, C; Yu, L; Zheng, L, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 8 (88.89) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, C | 1 |
| Bian, Y | 1 |
| Lu, B | 1 |
| Wang, D | 1 |
| Azami, NLB | 1 |
| Wei, G | 1 |
| Ma, F | 1 |
| Sun, M | 1 |
| Li, S | 2 |
| Wu, X | 1 |
| Ma, Y | 2 |
| Zhang, H | 1 |
| Chen, W | 2 |
| Zhao, Y | 1 |
| Sun, N | 1 |
| Song, X | 1 |
| Zhu, J | 1 |
| Wang, T | 1 |
| Wang, Z | 1 |
| Yu, Y | 2 |
| Ren, J | 1 |
| Chen, H | 1 |
| Zhan, T | 1 |
| Tian, J | 1 |
| Ma, C | 1 |
| Huang, J | 1 |
| Wang, J | 1 |
| Zhang, Y | 1 |
| Yang, B | 1 |
| Tang, J | 1 |
| Wang, L | 1 |
| Shi, M | 2 |
| Feng, S | 1 |
| Zhang, T | 1 |
| Han, H | 1 |
| Yu, L | 1 |
| Gong, L | 1 |
| Wang, C | 1 |
| Hu, N | 1 |
| Tang, Y | 1 |
| Zheng, L | 1 |
| Dai, X | 1 |
| Li, Y | 1 |
| Xu, Q | 1 |
| Fan, Y | 1 |
| Loor, JJ | 1 |
| Liang, Y | 1 |
| Lv, H | 1 |
| Sun, X | 1 |
| Jia, H | 1 |
| Xu, C | 1 |
| Shen, C | 1 |
| Pan, Z | 1 |
| Wu, S | 1 |
| Zheng, M | 1 |
| Zhong, C | 1 |
| Xin, X | 1 |
| Lan, S | 1 |
| Zhu, Z | 1 |
| Liu, M | 1 |
| Wu, H | 1 |
| Huang, Q | 1 |
| Zhang, J | 1 |
| Liu, Z | 1 |
| Si, Y | 1 |
| Tu, H | 1 |
| Deng, Z | 1 |
| Liu, H | 1 |
| Zhong, Y | 1 |
| Guo, J | 1 |
| Cai, J | 1 |
| Xian, S | 1 |
| Liu, Q | 1 |
| Yu, F | 1 |
| Yu, N | 1 |
| Wang, F | 1 |
9 other studies available for emodin and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Rhubarb free anthraquinones improved mice nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome.
Topics: Animals; Anthraquinones; Emodin; Inflammasomes; Inflammation; Mice; NLR Family, Pyrin Domain-Contain | 2022 |
Prediction and verification of the active ingredients and potential targets of Erhuang Quzhi Granules on non-alcoholic fatty liver disease based on network pharmacology.
Topics: Animals; Drugs, Chinese Herbal; Emodin; Lipids; Mice; Molecular Docking Simulation; Network Pharmaco | 2023 |
A novel small molecule AdipoR2 agonist ameliorates experimental hepatic steatosis in hamsters and mice.
Topics: AMP-Activated Protein Kinases; Animals; Cricetinae; Diet, High-Fat; Emodin; Hep G2 Cells; Hepatocyte | 2023 |
Study on the mechanism of Shuganzhi Tablet against nonalcoholic fatty liver disease and lipid regulation effects of its main substances in vitro.
Topics: Animals; Cholesterol; Diet, High-Fat; Emodin; Hesperidin; Lipid Metabolism; Lipids; Liver; Non-alcoh | 2023 |
Active ingredients of Erhuang Quzhi Granules for treating non-alcoholic fatty liver disease based on the NF-κB/NLRP3 pathway.
Topics: Animals; Curcumin; Emodin; Inflammasomes; Molecular Docking Simulation; Molecular Structure; NF-kapp | 2023 |
Radix Polygoni Multiflori and Its Main Component Emodin Attenuate Non-Alcoholic Fatty Liver Disease in Zebrafish by Regulation of AMPK Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 2020 |
Aloin protects mice from diet-induced non-alcoholic steatohepatitis via activation of Nrf2/HO-1 signaling.
Topics: Amino Acids; Animals; Apoptosis; Biomarkers; Choline Deficiency; Diet; Dietary Fats; Emodin; Gene Ex | 2021 |
Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Topics: Animals; Cassia; Diet, High-Fat; Dose-Response Relationship, Drug; Emodin; Glucose; Hepatocytes; Inf | 2021 |
[Emodin worsens methionine-choline-deficient diet-induced non-alcoholic fatty liver disease in mice].
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Choline; Diet; Emodin; Live | 2015 |